VTYX - CIK 0001851194
The table below shows Ventyx Biosciences, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $31.97M | $32.30M | $28.08M | $61.77M | $40.92M | $141.90M |
| Short-term investments | $160.67M | $176.66M | $200.73M | $213.06M | $198.51M | $160.68M |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $201.09M |
| $219.32M |
| $242.56M |
| $289.41M |
| $256.93M |
| $319.76M |
| Property, plant & equipment | $501.00K | $549.00K | $522.00K | $703.00K | $762.00K | $828.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $211.47M | $230.01M | $253.48M | $301.10M | $309.19M | $332.08M |
| Accounts payable | $993.00K | $913.00K | $2.32M | $2.29M | $6.58M | $5.58M |
| Total current liabilities | $11.26M | $11.47M | $12.39M | $12.30M | $18.10M | $14.53M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $20.10M | $20.63M | $21.85M | $22.33M | $28.40M | $25.08M |
| Retained earnings | -$631.57M | -$608.74M | -$581.75M | -$524.96M | -$489.71M | -$457.76M |
| Total equity | $191.36M | $209.38M | $231.63M | $278.77M | $280.80M | $307.00M |